Michael Bishop, MD, University of Chicago, Chicago, IL, discusses the importance of finding therapies to prevent relapse in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) following bone marrow transplantation (BMT). Prof. Bishop explains that combining various immune-modifying modalities such as bispecific antibodies and CAR-T therapy can improve outcomes in relapsed/refractory (R/R) patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть